By Daniella Parra Promontory Therapeutics Inc. completed enrollment of 109 late-stage metastatic castration-resistant prostate cancer patients for its Phase 2 trial of PT-112, which assesses its efficacy in patients who have undergone prior treatments, the company said. PT-112 is a...

By Karen Roman Potbelly Corporation (Nasdaq: PBPB), the neighborhood sandwich shop company originally from Chicago, reported its total revenue grew 4.7% to $125.7 million in the last quarter of 2023, compared to $120.2 million in 2022. Average Weekly Sales (AWS)...

By Daniella Parra Grove Collaborative Holdings, Inc. (NYSE: GROV) reported their Fourth Quarter Adjusted EBITDA of $0.1 million, positive for the second quarter in a row, and a record net revenue per order of $66.83. The sustainable consumer products company...

By Karen Roman a.k.a. Brands Holding Corp. (NYSE: AKA), a company that accelerates next generation fashion brands, announced its U.S. net sales grew 11.6% on the last quarter of 2023 and its total net sales decreased 0.1% to $148.9 million,...

By Daniella Parra Sparrow Pharmaceuticals continues its PROST! Phase 2 clinical trial for treating polymyalgia rheumatica (PMR) with SPI-62 and prednisolone, adding a fourth cohort, they said. PMR, an autoimmune disorder common among the elderly, traditionally treated with steroids like...

By Ambassador Marko Đurić Serbia has undergone a profound transformation over the past decade. Spearheaded by President Aleksandar Vučić’s vision of economic development and propelled by strategic reforms, our country’s economy has been booming as it charts a new course...

By Karen E. Roman Apollomics, Inc. (Nasdaq: APLM), a biopharmaceutical company that develops medicines for difficult-to-treat cancers, said it appointed Matthew Plunkett, Ph.D., as Chief Financial Officer. Dr. Plunkett has over 25 years of strategic and financial experience within the...

By Exec Edge Editorial Staff RBC Capital analyst Shagun Singh maintained Zynex, Inc. (Nasdaq:ZYXI) with an outperform rating and raised its price target from $13 to $15. Meanwhile, HC Wainwright & Co. analyst Yi Chen maintained a buy rating and...

By Daniella Parra FIGS, Inc. (NYSE: FIGS) said fourth quarter net revenue was $144.9 million and a reclassification negatively impacted net revenues by $4.7 million. Gross margin was 67.5%, a decrease of 70 basis points and operating expenses were $83.6...

By Daniella Parra Vivani Medical, Inc. (Nasdaq: VANI) reported promising preclinical data on NPM-115, a miniature exenatide implant for chronic weight management. The company focuses on GLP-1 implants for obesity treatment due to their potential to improve patient outcomes, which...